SCHEMBL5658564

SCHEMBL5658564

NC(=O)C1CN(C2CCNCC2)CCN1C(=O)[CH]Cc1ccc2[nH]ncc2c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
ROCK2 O75116 12/20 0.36
RPS6KB1 P23443 1/20 0.35
CLK2 P49760 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
STK17A Q9UEE5 1/20 0.35
DRD4 P21917 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
MAPK1 P28482 1/20 0.34
GRIN2B Q13224 3/20 0.34
ROCK1 Q13464 3/20 0.34
CCR2 P41597 1/20 0.34
CYP3A4 P08684 1/20 0.34
CALCRL Q16602 1/20 0.34
NEK2 P51955 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5660903 0.95 ROCK2 (0.36) SLC6A2SLC6A4SLC6A3ROCK2RPS6KB1
SCHEMBL5660887 0.86 PARP1 (0.38) SLC6A2SLC6A4SLC6A3CYP3A4CALCRL
SCHEMBL5658200 0.85 CYP3A4 (0.34) CYP3A4CALCRL
SCHEMBL5660053 0.85 CALCA (0.31)
SCHEMBL5656816 0.85 PARP1 (0.30)
SCHEMBL5657887 0.84 CYP3A4 (0.35) SLC6A2SLC6A4SLC6A3ROCK2RPS6KB1
SCHEMBL3602596 0.83 CYP2D6 (0.41) SLC6A2SLC6A4SLC6A3ROCK2DRD4
SCHEMBL5659610 0.82 CALCRL (0.36) SLC6A2SLC6A4SLC6A3ROCK2RPS6KB1
SCHEMBL5658079 0.80 ROCK2 (0.38) ROCK2RPS6KB1CLK2CLK4STK17A
SCHEMBL5661183 0.77 ACACB (0.42) ROCK2CYP3A4CALCRL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US claimed
US-7205294-B2 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-17 US disclosed
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BDKRB1, BDKRB2, CALCRL SLC6A2 496/4885SLC6A4 518/4885SLC6A3 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.